

A blue horizontal banner with an orange circle on the left side, containing the text 'PRESS RELEASE' in white capital letters.

PRESS RELEASE

Sosei Heptares to present at 37th Annual J.P. Morgan Healthcare Conference in San Francisco

Tokyo, Japan and London, UK, 27 December 2019 – Sosei Group Corporation (“the Company”; TSE: 4565), today announced its Chief Financial Officer, Chris Cargill, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 7, 2019.

The presentation will begin at 9:30 a.m. Pacific Time in the Elizabethan A/B room at the Westin St. Francis Hotel. The presentation will be webcast live in English and can be accessed [here](#) or via the investor section of the Company’s Home Page, www.soseiheptares.com. A replay and presentation slides will also be archived on the site following the event.

– Ends –

About Sosei Heptares

We are an international biopharmaceutical group focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR[®] technology and structure-based drug design platform capabilities. The Company is advancing a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications. Its leading clinical programs include partnered candidates aimed at the symptomatic treatment of Alzheimer’s disease (with Allergan) and next generation immuno-oncology approaches to treat cancer (with AstraZeneca). Our additional partners and collaborators include Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. The Company is headquartered in Tokyo, Japan with R&D facilities in Cambridge, UK and Zurich, Switzerland.

“Sosei Heptares” is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit www.soseiheptares.com.

Enquiries:

Sosei Heptares

Investor Relations and Corporate Communications

Shinichiro Nishishita, Yu Okada

+81 (0)3 5210 3399

IR@SoseiHeptares.com

Citigate Dewe Rogerson (for international media)

Mark Swallow, David Dible

+44 (0)20 7638 9571

SoseiHeptares@citigatedewerogerson.com

A solid orange circle on the left side of the page.

PRESS RELEASE

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.